3Mes·

New addition to the depot

$LNTH (-0,47%)
Lantheus Holdings


EUR 6.59 bn market cap

P/E RATIO 18

2-digit earnings growth forecast for the coming years


Broadly speaking, the company is involved in radiopharmaceutical oncology and precision diagnostics, etc.


The radiopharmaceutical oncology products support medical professionals in detecting, combating and monitoring cancer.


Dis precision diagnostics products help healthcare professionals detect and track diseases at an early stage - when it matters most.


In addition to diagnostic products, there are also therapeutic products and some in the pipeline.


Many of you will come into contact with the products at an older age (although I wouldn't wish it on anyone). Be it because of prostate cancer or to visualize the coronary arteries during a check-up.

attachment
attachment
attachment
attachment
attachment
attachment
11.09
Lantheus Hldg logo
Acquistato x50 a 99,83 USD
4.991,28 USD
13
5 Commenti

immagine del profilo
Have you ever made a comparison with $EUZ? I would actually consider them to be ahead in the field of radiopharmaceuticals and diagnostics🤔.
1
Mostra la risposta
immagine del profilo
Looks like a safe bet🤔 I took a look at the forecasts for sales and earnings growth, debt and equity. Will be on the watch list! Thank you.
Mostra la risposta
immagine del profilo
what do you think of the current rating?
Partecipa alla conversazione